Vaccines Market Size, Share, and Growth Forecast Overview Through 2034

According to a report published by Fortune Business Insights, the global vaccines market size was valued at USD 86.06 billion in 2024 and is expected to grow from USD 88.92 billion in 2025 to USD 178.81 billion by 2032, registering a compound annual growth rate (CAGR) of around 10.5% during the forecast period. This rapid growth is attributed to the increasing prevalence of infectious diseases, expanding vaccination programs worldwide, and rising investments by governments and pharmaceutical companies.

The global vaccines market is experiencing significant growth as governments, healthcare organizations, and pharmaceutical companies increasingly focus on preventing infectious diseases through immunization programs. Vaccines remain one of the most effective public health interventions, protecting millions of people worldwide from life-threatening illnesses. Rising awareness of preventive healthcare, growing immunization initiatives, and technological advancements in vaccine development are among the key factors driving market expansion. According to Fortune Business Insights, the global vaccines market is projected to witness strong growth over the coming years due to increasing investment in research and development and the introduction of innovative vaccine technologies.

The COVID-19 pandemic played a major role in accelerating vaccine research and production capabilities globally. It also increased awareness about the importance of immunization, encouraging countries to strengthen their healthcare infrastructure and vaccination strategies. As a result, the vaccines industry continues to benefit from sustained demand for immunization programs targeting diseases such as influenza, hepatitis, human papillomavirus (HPV), and pneumococcal infections.

Additionally, technological advancements such as mRNA vaccines, recombinant vaccines, and viral vector vaccines are transforming the industry. These technologies enable faster vaccine development and improved effectiveness, which further supports market growth.

Information Source: https://www.fortunebusinessinsights.com/industry-reports/vaccines-market-101769

Key Market Drivers

One of the major factors fueling the growth of the vaccines market is the increasing incidence of infectious diseases worldwide. Governments and international organizations are implementing large-scale immunization programs to reduce disease burden and improve public health outcomes. For instance, initiatives led by global health organizations and national health agencies are expanding vaccination coverage across both developed and developing countries.

Another important driver is the growing focus on pediatric vaccination programs. Childhood immunization schedules now include vaccines for several diseases such as measles, mumps, rubella, polio, rotavirus, and hepatitis. Governments are also introducing adult vaccination programs to prevent diseases such as influenza, shingles, and human papillomavirus.

Furthermore, the expansion of healthcare infrastructure in emerging economies is boosting vaccine accessibility. Countries in Asia Pacific, Latin America, and Africa are investing heavily in immunization campaigns and improving cold chain logistics to ensure effective vaccine distribution.

Market Segmentation

The vaccines market can be segmented based on type, route of administration, disease indication, age group, and distribution channel. By type, the market includes live attenuated vaccines, inactivated vaccines, recombinant vaccines, mRNA vaccines, viral vector vaccines, and toxoid vaccines. Among these, recombinant and mRNA vaccines are gaining significant traction due to their high efficacy and faster development timelines.

In terms of route of administration, vaccines are primarily administered through parenteral injection or oral delivery. Parenteral vaccines currently dominate the market as they are widely used in routine immunization programs worldwide.

Based on disease indication, vaccines are developed to prevent both viral and bacterial diseases. Viral disease vaccines—such as those for influenza, hepatitis, HPV, measles, and rotavirus—represent a large share of the market due to the high prevalence of viral infections globally.

The market is also segmented by age group, including pediatric and adult vaccines. Pediatric vaccines account for a substantial share because of mandatory childhood immunization programs across many countries.

Regional Insights

North America holds a significant share of the global vaccines market due to advanced healthcare infrastructure, strong government support for immunization programs, and the presence of major pharmaceutical companies. The United States, in particular, has a well-established vaccination framework and high healthcare spending, which contributes to regional market growth.

Europe also represents a key market due to strong regulatory frameworks and extensive immunization initiatives. Meanwhile, the Asia Pacific region is expected to experience the fastest growth during the forecast period. Factors such as a large population base, rising healthcare expenditure, and expanding vaccination campaigns in countries such as India and China are driving regional market expansion.

Competitive Landscape and Key Players

The vaccines market is highly competitive, with several global pharmaceutical companies investing heavily in research and development to expand their product portfolios. Strategic collaborations, mergers and acquisitions, and new product launches are common strategies adopted by leading companies to strengthen their market position.

Key players operating in the global vaccines market include:

• Pfizer Inc.

• GlaxoSmithKline plc (GSK)

• Sanofi

• Merck & Co., Inc.

• Moderna, Inc.

• AstraZeneca

• Serum Institute of India Pvt. Ltd.

• Bharat Biotech

• CSL Limited

• Sinopharm Group

These companies are actively engaged in developing innovative vaccines using advanced technologies such as mRNA platforms and recombinant DNA technology. Strong R&D capabilities and diverse product portfolios enable these companies to maintain a competitive edge in the global market.

Conclusion

The global vaccines market is expected to witness robust growth in the coming years, driven by rising awareness of preventive healthcare, increasing government immunization initiatives, and technological advancements in vaccine development. The growing demand for vaccines to combat infectious diseases, along with ongoing research into next-generation vaccine technologies, will continue to shape the industry. As pharmaceutical companies expand their vaccine portfolios and governments strengthen vaccination programs, the market is poised for sustained expansion over the forecast period.